Hughes syndrome/APS

Published on December 31, 2017   24 min

Other Talks in the Therapeutic Area: Immunology & Inflammation

My name's Graeme Hughes and I'm at the London Lupus centre at London Bridge Hospital shown on this slide, not the shard which is behind us but on the river. I'm also the editor of the Lupus Journal and some of the data in this short talk is going to come from that journal. So my talk now is on the Hughes syndrome or Antiphospholipid syndrome as we call it.
The title I've given it is "Past, present and future" and I'll be very brief in reviewing the history.
It's actually 34 years ago that we've first published the details of this in a number of journals, but basically the first publication was in the British Medical Journal in 1983 and we were also working on essays for Anticardiolipin and other antibodies.
And in the same year, towards the end of the year we published in The Lancet a paper on the assessment of Anticardiolipin antibodies which still is in use today, the detection by various methods. So this is the discovery of a syndrome which is characterized by a few things. One was particularly important and that is these patients had a tendency to clotting both in the veins and the arteries and also, this was a clear example where a group of antibodies were contributing to the problem.
These are some of my team, this was when I was at the Hammersmith Hospital and next to me on my left is Azis Garavie who was really a genius in the lab working at that time, and behind him is Nigel Harris from the Caribbean who joined the team and with Azis became instrumental in setting up the essays. And a number of people here were clinical fellows involved in our early work. But back left is Charles Mackwith Young who did some of our clinical studies of Antiphospholipid antibodies.